tirzepatide dosing compared to semaglutide Switching Tirzepatide: A Provider's Guide Early Dose Escalation of Tirzepatide
Description
Tirzepatide is a protein-based molecule that is sensitive to temperature, light, and contamination
A disproportionality analysis (Godfrey et al., JEADV 2025) found a reporting odds ratio of 1.73 for tirzepatide (95% CI: 1.42 to 2.09), and as high as 2.46 for semaglutide
The transition period involves weeks of subtherapeutic dosing as you titrate up, during which weight loss may slow or stall
Rapid heartbeat and dizziness
Kavir Matharu is GP Lead at MedExpress, with 10 years experience across a range of healthcare settings
By simultaneously activating GIP and GLP-1 pathways, tirzepatide enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite
